{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:57Z","timestamp":1787017077122,"version":"build-2736575974"},"reference-count":41,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Successful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational cohort study from the DANBIO registry. Patients were classified as originator-na\u00efve or originator-experienced. Retention rates of 1-year GP1111 treatment were explored (Kaplan-Meier). We identified baseline factors (at the time of switch) associated with withdrawal of GP1111 (multivariable Cox-regression analyses with HRs including originator treatment history). Changes in subjective and objective measures of disease activity 4 months before and after the switch were assessed in individual patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1605 patients (685 RA, 314 PsA and 606 AxSpA, median disease duration was 9 years, 37% in Clinical Disease Activity Index\/Ankylosing Spondylitis Disease Activity Score remission), 1171 were originator-na\u00efve. Retention rates at 1-year were 83% (95% CI: 81% to 85%) and 92% (95% CI: 90% to 95%) for the originator-na\u00efve and originator-experienced, respectively. GP1111 retention rates were higher in originator-experienced compared to originator-na\u00efve with RA (HR=0.4 (95% CI: 0.2 to 0.7)) and PsA (HR=0.2 (95% CI: 0.1 to 0.8)), but not significantly for AxSpA: HR=0.6 (95% CI: 0.3 to 1.2). Lower disease activity was associated with higher retention. Changes in disease activity preswitch and postswitch were close to zero.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world observational study of more than 1600 patients with inflammatory arthritis showed high 1-year retention following a nationwide infliximab biosimilar-to-biosimilar switch. Retention was higher in originator-experienced and in patients with low disease activity, suggesting outcomes to be affected by patient-related rather than drug-related factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002560","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T13:59:49Z","timestamp":1669211989000},"page":"e002560","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-7927","authenticated-orcid":false,"given":"Hafsah","family":"Nabi","sequence":"first","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hendricks","sequence":"additional","affiliation":[{"name":"Danish Hospital for Rheumatic Disease, University Hospital of Southern Denmark, S\u00f8nderborg, Syddanmark, Denmark"},{"name":"Department of Regional Health Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Vendelbo","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark"},{"name":"Department of Internal Medicine, R\u00f8nne Hospital, R\u00f8nne, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Kristian","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine M, Svendborg Hospital, Svendborg, Syddanmark, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-5919","authenticated-orcid":false,"given":"S\u00f8ren Andreas","family":"Just","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Svendborg Hospital, Svendborg, Syddanmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla","family":"Danebod","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-6283","authenticated-orcid":false,"given":"Heidi Lausten","family":"Munk","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Odense University Hospital, Odense C, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-5234","authenticated-orcid":false,"given":"Salome","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Manilo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Colic","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zealand University Hospital, K\u00f8ge, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"Linauskas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Denmark Regional Hospital, Hj\u00f8rring, Denmark"},{"name":"Department of Clinical Medicine, Aalborg Universitet, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia H\u00f8ger","family":"Thygesen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Brot","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren H\u00f8gberget","family":"Kalisz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Lomborg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Vejle Hospital Lilleb\u00e6lt, Vejle, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-6517","authenticated-orcid":false,"given":"Stavros","family":"Chrysidis","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny Lillelund","family":"Raun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Lilleb\u00e6lt, Fredericia, Kolding, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Denmark Regional Hospital, Hjorring, Nordjylland, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mehnert","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[{"name":"Zitelab Aps, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-8482","authenticated-orcid":false,"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"2025090313162454000_8.2.e002560.1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","article-title":"Biosimilar-to-Biosimilar switching: what is the rationale and current experience?","volume":"81","author":"Mysler","year":"2021","journal-title":"Drugs"},{"key":"2025090313162454000_8.2.e002560.2","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1007\/s12325-020-01472-1","article-title":"The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence","volume":"37","author":"Feagan","year":"2020","journal-title":"Adv Ther"},{"key":"2025090313162454000_8.2.e002560.3","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/rheumatology\/kex277","article-title":"Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology"},{"key":"2025090313162454000_8.2.e002560.4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000900"},{"key":"2025090313162454000_8.2.e002560.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"2025090313162454000_8.2.e002560.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208786"},{"key":"2025090313162454000_8.2.e002560.7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0981-6"},{"key":"2025090313162454000_8.2.e002560.8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-018-1646-4","article-title":"A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy","volume":"20","author":"Cohen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313162454000_8.2.e002560.9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjd.19013","article-title":"Switching from one infliximab biosimilar (CT\u2010P13) to another infliximab biosimilar (Sb2) in patients with chronic plaque psoriasis","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090313162454000_8.2.e002560.10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.semarthrit.2020.02.007","article-title":"Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice","volume":"50","author":"Lauret","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313162454000_8.2.e002560.11","article-title":"PMO-20 the IBD biosimilar to biosimilar switching study (iBiSS)","volume":"70","author":"Harris","year":"2021","journal-title":"Gut"},{"key":"2025090313162454000_8.2.e002560.12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ibd\/izab099","article-title":"Multiple switches from the Originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025090313162454000_8.2.e002560.13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14712598.2021.1963435","article-title":"Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe","volume":"22","author":"Agboton","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025090313162454000_8.2.e002560.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"2025090313162454000_8.2.e002560.15","first-page":"191","article-title":"Efficacy and safety of adalimumab Biosimilar (Exemptia) in moderate-to-severe Steroid-Refractory ulcerative colitis patients: real-life outcomes in resource-constrained setting at 24-Weeks follow-up","volume":"13","author":"Chandra","year":"2019","journal-title":"Biologics"},{"key":"2025090313162454000_8.2.e002560.16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.40516","article-title":"Open-Label, Non-Mandatory transitioning from Originator etanercept to Biosimilar Sb4: six-month results from a controlled cohort study","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313162454000_8.2.e002560.17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for Biosimilar discontinuation after Open\u2010Label transition from reference infliximab to Biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313162454000_8.2.e002560.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211937"},{"key":"2025090313162454000_8.2.e002560.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219951"},{"key":"2025090313162454000_8.2.e002560.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"2025090313162454000_8.2.e002560.21","unstructured":"The Danish regions, rads, guidelines for use of biosimilar infliximab and etanercept,, 2016. Available: https:\/\/www.regioner.dk\/media\/3488\/rads-notat-om-anvendelsen-af-biosimilaere-juni-2016.pdf"},{"key":"2025090313162454000_8.2.e002560.22","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99490"},{"key":"2025090313162454000_8.2.e002560.23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/CLEP.S141438","article-title":"Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish national patient registry","volume":"9","author":"Ibfelt","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2025090313162454000_8.2.e002560.24","doi-asserted-by":"crossref","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2025090313162454000_8.2.e002560.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"2025090313162454000_8.2.e002560.26","unstructured":"RStudio - RStudio. Available: https:\/\/www.rstudio.com\/products\/rstudio\/ [Accessed 14 Feb 2022]."},{"key":"2025090313162454000_8.2.e002560.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-0981-6","article-title":"A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090313162454000_8.2.e002560.28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/03009742.2018.1444199","article-title":"Biological treatment in ankylosing spondylitis in the Nordic countries during 2010\u20132016: a collaboration between five biological registries","volume":"47","author":"Glintborg","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2025090313162454000_8.2.e002560.29","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-016-0601-0","article-title":"Pharmacoeconomics of biosimilars: what is there to gain from them?","volume":"18","author":"Ara\u00fajo","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313162454000_8.2.e002560.30","doi-asserted-by":"crossref","first-page":"iv49","DOI":"10.1093\/rheumatology\/kex276","article-title":"Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons","volume":"56","author":"Uhlig","year":"2017","journal-title":"Rheumatology"},{"key":"2025090313162454000_8.2.e002560.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"2025090313162454000_8.2.e002560.32","unstructured":"Troein P , Newton M , Scott K . The impact of Biosimilar competition in Europe, 2020. Available: https:\/\/ec.europa.eu\/health\/system\/files\/2021-01\/biosimilar_competition_en_0.pdf [Accessed 25 May 2022]."},{"key":"2025090313162454000_8.2.e002560.33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000876"},{"key":"2025090313162454000_8.2.e002560.34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14712598.2017.1238454","article-title":"The design of clinical trials to support the switching and alternation of biosimilars","volume":"16","author":"Faccin","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2025090313162454000_8.2.e002560.35","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acr.22860","article-title":"Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials","volume":"68","author":"Vashisht","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090313162454000_8.2.e002560.36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.16312","article-title":"Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar Sb2 in patients with inflammatory bowel disease: a 12-month prospective cohort study","volume":"53","author":"Trystram","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090313162454000_8.2.e002560.37","doi-asserted-by":"crossref","first-page":"otab022","DOI":"10.1093\/crocol\/otab022","article-title":"The efficacy and safety of switching from originator infliximab to single or double switch biosimilar among a nationwide cohort of inflammatory bowel disease patients","volume":"3","author":"Khan","year":"2021","journal-title":"Crohn's Colitis"},{"key":"2025090313162454000_8.2.e002560.38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/cts.13131","article-title":"Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study","volume":"15","author":"Mazza","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2025090313162454000_8.2.e002560.39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.17235\/reed.2020.6693\/2019","article-title":"Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study","volume":"112","author":"Ribaldone","year":"2020","journal-title":"Rev Esp Enferm Dig"},{"key":"2025090313162454000_8.2.e002560.40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40259-020-00446-7","article-title":"Interchangeability of biosimilars: what level of clinical evidence is needed to support the interchangeability designation in the United States?","volume":"34","author":"Alvarez","year":"2020","journal-title":"BioDrugs"},{"key":"2025090313162454000_8.2.e002560.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2306"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:16:38Z","timestamp":1756930598000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,23]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/rmdopen-2022-002560"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002560","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}